Daewoong Pharmaceutical

Checkmate Capital Group and KAIST Venture Investment Holdings Announce Partnership & Selection as TIPS Operator

Retrieved on: 
Monday, June 27, 2022
Agriculture, KAIST, Biotechnology, Technology, Engineering, GLOBE, Daewoong Pharmaceutical, Partnership, Checkmate, TIPS, Program, Financial services, Science

LOS ANGELES and SEOUL, South Korea, June 26, 2022 (GLOBE NEWSWIRE) -- A consortium formed by KAIST Venture Investment Holdings and Checkmate Capital Group has been selected as a program operator for South Koreas Tech Incubator Program for Startups (TIPS).

Key Points: 
  • LOS ANGELES and SEOUL, South Korea, June 26, 2022 (GLOBE NEWSWIRE) -- A consortium formed by KAIST Venture Investment Holdings and Checkmate Capital Group has been selected as a program operator for South Koreas Tech Incubator Program for Startups (TIPS).
  • Through our joint participation as a TIPS program operator, KAIST and Checkmate look forward to helping early-stage Korean enterprises achieve global success, added Checkmate Managing Director Jay Ryu.
  • KAIST Venture Investment Holdings CEO Henry Chung said, We are excited to partner with Checkmate as our foreign advisor.
  • Checkmate Capital is an investment and strategic advisory group managing family office assets with a global commercial and financial network.

Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis

Retrieved on: 
Friday, June 24, 2022
PRS, Diagnosis, FDA, View, Patient, CEO, Liver, IPF, HIV disease progression rates, American Thoracic Society, Pulmonary fibrosis, Growth, Disease, Kidney, Idiopathic pulmonary fibrosis, Food, FVC, Clinical trial, IND, Vital capacity, Survival, Skin, Collagen, Human, Idiopathic disease, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Multimedia, Degenerative disease, Pharmaceutical industry, Daewoong Pharmaceutical

SEOUL, South Korea, June 24, 2022 /PRNewswire/ -- Daewoong announced that the U.S. Food and Drug Administration (FDA) had approved the IND for the phase 2 clinical trial of DWN12088, a PRS (Prolyl-tRNA Synthetase) inhibitor for patients with idiopathic pulmonary fibrosis. Daewoong plans to start the clinical trial this September, and with this enters its global phase 2 clinical trial for a new drug for idiopathic pulmonary fibrosis.

Key Points: 
  • Daewoong plans to start the clinical trial this September, and with this enters its global phase 2 clinical trial for a new drug for idiopathic pulmonary fibrosis.
  • This phase 2 clinical trial will be conducted as a multinational clinical study simultaneously in the United States and South Korea to evaluate the safety and efficacy of DWN12088.
  • It has been designated as an orphan drug for idiopathic pulmonary fibrosis by the U.S. FDA in 2019.
  • "The existing treatments of Idiopathic pulmonary fibrosis still have high unmet medical needs," said Sengho Jeon, CEO of Daewoong Pharmaceutical.

Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed

Retrieved on: 
Thursday, June 2, 2022
Biotechnology, Luxury, Health, General Health, Women, Pharmaceutical, Research, Retail, Consumer, Science, Clinical Trials, Millennials, Friction, Adult, III, Carruthers, Safety, Food, LinkedIn, Annual report, CEO, Security (finance), Allergan, Inc., U.S. Securities and Exchange Commission, Nasdaq, Sale, Development, Growth, Patient, Publication, Private Securities Litigation Reform Act, Technology, COVID-19, Dermatology, Adoption, Incidence, NASDAQ, SEC, Twitter, MD, Population, Toxin (comics), Efficiency, Patient satisfaction, Instagram, Skin, Regulation of tobacco by the U.S. Food and Drug Administration, Color, Botulinum toxin, Ageing, Research and development, Medical device, Pharmaceutical industry, Kerosene, Daewoong Pharmaceutical, Facebook, Research

Data showed that millennials achieved higher results across all effectiveness measurements and time periods, hitting statistical significance at several points.

Key Points: 
  • Data showed that millennials achieved higher results across all effectiveness measurements and time periods, hitting statistical significance at several points.
  • On the Glabellar Line Scale at maximum frown, 100% of millennials achieved greater than 1-point improvement on days 7, 14 and 30.
  • These results show that not only is Jeuveau well-tolerated by patients, it also demonstrated higher efficacy values in millennials across every measurable endpoint and every time point.
  • We believe the findings of this analysis validate our millennial-focused strategy and will encourage broader adoption of Jeuveau among this demographic.

AffyXell Expands its Strategic Partnership With GenScript ProBio

Retrieved on: 
Monday, May 16, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, DNA, HKG, Lentivirus, Patient, Daewoong Pharmaceutical, CDMO, Stem cell, GenScript Biotech, Research, Partnership, AIM, Group, Fine chemical, Pharmaceutical industry, Vaccine, Asota avacta

AffyXell and GenScript ProBio are extending their strategic manufacturing partnership, which they entered into in December 2021, that covers AffyXells first drug development programme to include additional future programmes.

Key Points: 
  • AffyXell and GenScript ProBio are extending their strategic manufacturing partnership, which they entered into in December 2021, that covers AffyXells first drug development programme to include additional future programmes.
  • Dr Alastair Smith, Chief Executive Officer of Avacta, commented: This is an important strategic partnership for AffyXell with a world leading contract development and manufacturing partner.
  • The fact that GenScript ProBio are prepared to take a strategic equity stake in AffyXell is a very strong validation of the potential for AffyXells next generation cell and gene therapies, and the future valuation of the business.
  • Dr Brian Min, Chief Executive Officer of GenScript ProBio commented: We are pleased to partner with AffyXell and are honored to support this next-generation cell therapy project with GenScript ProBios stable and high-yield viral vector platform.

Evolus Reports First Quarter 2022 Results and Provides Business Update

Retrieved on: 
Tuesday, May 10, 2022
Women, Specialty, Biotechnology, Other Health, Health, Consumer, Pharmaceutical, General Health, Retail, Momentum, Friction, COVID-19, Adjusted gross income, Cyprus Securities and Exchange Commission, Investment, Mission statement, Income, Private Securities Litigation Reform Act, GAAP, Instagram, Twitter, Nasdaq, NASDAQ, Food, 1969–70 1. Slovenská národná hokejová liga season, Trial of the century, Depreciation, Security (finance), Program, Annual report, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, Forecasting, Marketing, LinkedIn, Efficiency, Technology, Growth, Investor relations, Renewable energy, Cryptocurrency, Pharmaceutical industry, Video game, Insurance, Risk management, Bank, Daewoong Pharmaceutical, Facebook

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.
  • Momentum in the companys business continues to build with its lead metrics reaching all-time highs this quarter.
  • Evolus added 575 new customer accounts in the first quarter, the highest quarterly increase in the past two years.
  • This program provides Evolus with the opportunity to offer the first multi-strength neurotoxin, giving customers and consumers increased treatment options.

Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake

Retrieved on: 
Wednesday, April 13, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Daewoong Pharmaceutical, Group, Intellectual property, AIM, Medication, B cell, Therapy, MSC, Pharmaceutical industry, Fine chemical, Asota avacta

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avactas shareholding in AffyXell Therapeutics (AffyXell), a joint venture between Avacta and Daewoong Pharmaceutical (Daewoong) in South Korea.

Key Points: 
  • Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer and pre|CISION platforms, is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avactas shareholding in AffyXell Therapeutics (AffyXell), a joint venture between Avacta and Daewoong Pharmaceutical (Daewoong) in South Korea.
  • Avacta has successfully developed and characterised Affimer proteins against the first target for AffyXell and has now transferred intellectual property relating to Affimer proteins against that target into AffyXell, triggering an agreed milestone in the joint venture agreement.
  • In exchange for this, Avacta has received an increase in its equity stake in AffyXell, which was diluted from its founding equity stake in February 2021 when AffyXell completed a Series A financing of $7.3 million from a group of venture funds in February 2021.
  • AffyXell was established in January 2020 by Avacta and Daewoong as a joint venture to develop novel mesenchymal stem cell (MSC) therapies.

Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail

Retrieved on: 
Thursday, March 3, 2022
Cosmetics, Retail, Health, Other Health, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, View, Forward-looking statement, Twitter, Food, Corporation, Security (finance), U.S. Securities and Exchange Commission, LinkedIn, Instagram, Growth, Efficiency, Corporate development, COVID-19, Friction, CEO, Â, Technology, NASDAQ, Management, Bank, Daewoong Pharmaceutical, Facebook

Lauren has had an incredible impact on this company, and we are grateful for her many contributions to Evolus, said David Moatazedi, President and CEO at Evolus.

Key Points: 
  • Lauren has had an incredible impact on this company, and we are grateful for her many contributions to Evolus, said David Moatazedi, President and CEO at Evolus.
  • Lauren has been instrumental in helping us build this company from a development stage organization to a fast-growing and well-funded commercial business.
  • Her experience and dedication have been key in helping Evolus get to the strong financial position we enjoy today.
  • Lauren has been a trusted partner over the past four years, and we wish her the very best in retirement.

Evolus Names Christos Monovoukas Senior Vice President of Corporate Development

Retrieved on: 
Tuesday, March 1, 2022
Luxury, Women, FDA, Biotechnology, Fashion, Health, Consumer, Pharmaceutical, Retail, Private Securities Litigation Reform Act, Olympus Corporation, Regulation of tobacco by the U.S. Food and Drug Administration, Leadership, Employment, View, Forward-looking statement, Twitter, Food, Corporation, Security (finance), U.S. Securities and Exchange Commission, LinkedIn, Instagram, LLC, New business development, Efficiency, Corporate development, COVID-19, Friction, Senior, CEO, RSU, Smith & Nephew, Technology, Nasdaq, Acceleration, NASDAQ, Management, Daewoong Pharmaceutical, Facebook

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has appointed Christos Monovoukas as Senior Vice President, Corporate Development, effective February 28, 2022.

Key Points: 
  • Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has appointed Christos Monovoukas as Senior Vice President, Corporate Development, effective February 28, 2022.
  • Monovoukas will join Evolus Leadership Team reporting to CEO David Moatazedi and support the company's strategic goals and growth strategy.
  • Prior to joining Evolus, Monovoukas served as Vice President of Global M&A and Corporate Development at Olympus Corporation.
  • Before that, he served as Vice President of New Business Development at both Smith & Nephew and Pharos, LLC.

Oncocross Begins Clinical Trial for AI-Developed Drug for Sarcopenia

Retrieved on: 
Friday, February 25, 2022
Oncology, Health, Technology, Other Technology, Clinical Trials, Pharmaceutical, Biotechnology, RAPTOR, Sarcopenia, Conditional sentence, Prognosis, Pharmacokinetics, International Classification of Diseases, Clinical trial, Drug development, Duchenne, Safety, Disease, Trial of the century, Cancer, Muscle, Biomarker, IND, ALS, Daewoong Pharmaceutical, Ageing, Patient, Quality of life, CEO, Duchenne muscular dystrophy, Medical device, Pharmaceutical industry

Oncocross , an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for OC514 targeting muscular diseases including sarcopenia.

Key Points: 
  • Oncocross , an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for OC514 targeting muscular diseases including sarcopenia.
  • Sarcopenia is a disease characterized by progressive loss of skeletal muscle mass and strength, thereby deteriorating normal physical function.
  • Upon completion of phase I, Oncocross plans to conduct phase II clinical trials for OC514, targeting cancer patients accompanying sarcopenia.
  • OC514 has a significant meaning for us since it is one of the first AI-driven drug candidates for sarcopenia that is going into clinical trials globally.

STAT Inhibitors Drug Pipeline Markets Research 2022: Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Apoptosis, News, Nausea, Discovery, Daewoong Pharmaceutical, Jiangsu Hengrui Medicine, STAT3, III, STAT5, Protein, Hepatic stellate cell, STAT5B, Acquisition, II, Infection, Clinical trial, STAT1, JAK3, STAT6, STAT5A, JAK2, COVID, STAT inhibitors, Niclosamide, Therapy, Oxidative phosphorylation, JAK1, Tyrosine, Oligonucleotide, Signal, STAT, Vomiting, Fatigue, JAK, Peptidomimetic, Pharmaceutical industry

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e.
  • The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D.